Health Research Methods, Evidence, and Impact


Clive Kearon

M.D., M.R.C.P.I., F.R.C.P.C., Ph.D.

Professor, Medicine, McMaster University

Program Director, Clinician Investigator Program

Juravinski Hospital,
Room 115, 40 Wing,
711 Concession St,
Hamilton, ON, L8V 1C3
Canada

905.383.2251
905.574.7625
kearonc@mcmaster.ca

Academic Interests

Although his current clinical responsibilities primarily focus on the management of thromboembolic disorders, Dr. Kearon originally qualified in Ireland, trained as a respirologist and obtained a Ph.D. from McMaster University for studies relating to respiratory and exercise physiology.  He is currently a Professor in the Department of Medicine, an Associated Member in the Department of Clinical Epidemiology and Biostatistics at McMaster University, a Consultant with the Clinical Thromboembolism Service at the Juravinski Division of Hamilton Health Sciences, and Program Director of the Clinician Investigator Program, at McMaster.  He was a Career Investigator of the Canadian Institutes of Health Research and is now an Investigator of the Heart and Stroke Foundation of Canada.  Dr. Kearon is the recipient of two awards from the Canadian Institutes of Health Research for providing mentorship in the design and conduct of randomized controlled trials, and he is the recipient of the International Society on Thrombosis and Haemostasis' 14th Biennial Investigator Recognition Award (2009).  Dr. Kearon is involved in the critical appraisal of the medical literature, the development of practice guidelines, and is the chairperson for the current American College of Chest Physicians' guidelines for the treatment of venous thromboembolism.

Dr. Kearon's research focuses on clinical trials designed to optimize the diagnosis and treatment of thromboembolic disease.  Diagnostic studies are evaluating the ability of D-dimer blood tests to exclude the presence of deep vein thrombosis and pulmonary embolism.  Treatment studies are evaluating new ways to use unfractionated heparin for the acute treatment of venous thrombosis; the optimal duration of anticoagulation in subgroups of patients who have either a high, or a low risk of recurrent venous thrombosis; and the catheter-directed thrombolysis for the acute treatment of deep vein thrombosis.

Dr. Kearon is also undertaking studies to identify the clinical importance, and the management implication, of the presence of biochemical abnormalities that are known to be associated with thromboembolism ("thrombophilia").  Additional studies will try to refine how patients with venous thromboembolism are selected to long-term therapy so as to maximize benefit and minimize harm from bleeding.

Dr. Kearon's research is supported by the Heart and Stroke Foundation of Ontario, Canadian Institutes of Health Research, and the National Institute of Health.

Selected Publications

  1. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006;368:371-78.
  2. Kearon C, Ginsberg JS, Douketis J, Turpie AG, Bates SM, Lee AY et al. An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med. 2006;144:812-21.
  3. Kearon C, Julian JA, Kovacs MJ, Anderson DR, Wells P, MacKinnon B et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 2008;112:4432-36.
  4. Andreou ER, Koru-Sengul T, Linkins L, Bates SM, Ginsberg JS, Kearon C. Differences in clinical presentation of deep vein thrombosis in men and women. J Thromb Haemost. 2008;6:1713-19.
  5. Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006;296:935-42.
  6. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob G, Comerota AJ. Antithrombotic Thereapy for Venous Thromboembolic Disease.  ACCP Evidence-Based Clinical Practice Guidelines (Eighth Edition). Chest. 2008;133:454S-545S.
  7. Arnold DM, Anderson J, Kearon C. Preoperative risk assessment for bleeding and thromboembolism. Br Med J. 2009;339:b2299.
  8. Linkins L, O'Donnell M, Julian JA, Kearon C. Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. J Thromb Haemost. 2010;8:2201-7.
  9. Couturaud F, Leroyer C, Julian JA, Kahn SR, Ginsberg JS, Wells PS, Douketis JD, Mottier D, Kearon C. Factors that predict risk of thrombosis in relatives of patients with unprovoked venous thromboembolism. Chest. 2009;136:1537-45.
  10. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, Hirsh J, Kearon C. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. Br Med J. 2011;342:d3036.

Search for citations on Dr. Kearon on PubMed